Ropenefix Special Precautions

Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to Meropenem. As with all beta-lactam antibiotics rare hypersensitivity reactions have been reported.
As with other antibiotics, overgrowth of non-susceptible organisms may occur and repeated evaluation of each patient is necessary.
Rarely, pseudomembranous colitis has been reported with Meropenem FOR INJECTION USP as with virtually all antibiotics; therefore, its diagnosis should be considered in patients who develop diarrhoea in association with the use of Meropenem.
Meropenem may reduce serum valproic acid levels. Subtherapeutic levels may be reached in some patients. A positive direct or indirect Coombs test may develop.
Use in Patients with Renal insufficiency: See DOSAGE & ADMINISTRATION.
Use in Patients with Liver Disease: Patients with pre-existing liver disorders should have liver function monitored during treatment with Meropenem.
Effect on Ability to Drive or Operate Machinery: No data are available, but it is not anticipated that Meropenem will affect the ability to drive and operate machinery.
Use in Pregnancy: The safety of Meropenem in human pregnancy has not been established, although animal studies have not shown an adverse effect on the developing fetus. Meropenem should not be used in pregnancy unless the potential benefit justifies the potential risk to the foetus.
Meropenem is detectable at very low concentrations in animal breast milk. Meropenem should not be used in breastfeeding women unless the potential benefit justifies the potential risk to the baby.
Use in Children: Efficacy and tolerability in infants under 3 months old have not been established; therefore, Meropenem FOR INJECTION USP is not recommended for use below this age.